Skip to main content

Table 4 Results of a joint-based analysis

From: Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

 

TJC

SJC

SUV

TJC

SJC

SUV

TJC

SJC

SUV

 

(0M)

(0M)

(0M)

(3M)

(3M)

(3M)

(6M)

(6M)

(6M)

Rt shoulder

1

0

1.71±1.11

2

0

1.68±0.76

1

0

1.65±0.60

Lt shoulder

0

0

2.06±1.31

1

0

2.06±1.20

1

0

2.11±1.07

Rt elbow

1

2

1.63±1.05

3

3

1.48±0.77

5*

4

1.46±0.58

Lt elbow

2

3

2.05±1.50

5

4

1.70±1.15

5

5

1.64±1.06*

Rt wrist

7

9

2.69±1.24

2*

8

2.30±1.44

3

3*

1.92±1.11

Lt wrist

6

8

2.49±1.44

2

4

2.23±1.57

1*

2*

1.96±1.17

Rt knee

7

9

2.90±1.89

2*

4

1.98±0.82*

4

5

1.89±0.90*

Lt knee

7

7

2.58±1.82

1*

4

1.90±1.22*

2

5

1.84±1.05*

Rt hip

0

0

1.47±0.50

0

0

1.53±0.36

0

1

1.55±0.50

Lt hip

1

0

1.54±0.59

0

0

1.56±0.33

0

1

1.43±0.43

Rt ankle

4

5

1.95±1.21

3

3

1.67±0.99

4

3

1.55±0.91

Lt ankle

5

7

1.95±1.21

4

3

1.75±1.08

5

5

1.79±0.96

  1. The data are presented as the mean ± S.D.. *indicates a significant difference compared with the value observed at baseline (Wilcoxon signed rank-sum test, p < 0.05).